The Administration Core (Core A) will coordinate and support the programmatic, fiscal, oversight and developmental endeavors upon which the translational success of the SARC Sarcoma SPORE depends. The goals of the SPORE are to translate biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and particularly -advances in the treatment of sarcoma. The SARC Sarcoma SPORE is anchored by multiple researchers from SARC, Harvard, and MD Anderson Cancer Center, but also includes key individual researchers from Stanford University, Columbia University and The University of Michigan. The researchers represent medical and pediatric oncology and the projects explore both soft tissue and bone sarcomas. Four major projects are proposed: 1) Rational HDACi-based therapeutic strategies for the treatment of genetically complex STS;2) Developing effective combination therapies for malignant peripheral nerve sheath tumor (MPNST);3) Identification of biomarkers of response to G-protein coupled receptors and novei therapeutic targets in Ewing's sarcoma;and 4) Developing quantitative imaging biomarkers for assessing therapeutic response to sarcoma therapy. These projects are integrated and supported by 4 cores: 1) Administration, Evaluation and Planning;2) Tissue and Pathology; 3) Clinical Trials;and 4) Biostatistics. The SP0RE application outlines a Developmental Research Program that includes a plan for selection of new projects as well as 14 proposed developmental pilot projects. We also inciude a Career Development Program that outlines a mechanism for the identification and support of talented young investigators in translational or clinical sarcoma research. The projects and cores proposed in this application are highly integrated and are poised to take maximum advantage ofthe SPORE mechanism to achieve translational goals. This SPORE joins the foremost sarcoma investigators and state-of-the art research projects with the multi-institution, collaborative strength of SARC and commitments from leading institutions to produce successful translational advances in the diagnosis, treatment, and prevention of sarcoma.

Public Health Relevance

The SPORE progrann will advance sarcoma therapeutics by combining and integrating nation-wide translational research strengths. Success in this endeavor will require capable and well-supported administrative center, which will maximize opportunities for existing projects and cores, coordinate oversight ofthe SPORE, and encourage career development and development of promising new project concepts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA168512-02
Application #
8561222
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
2
Fiscal Year
2013
Total Cost
$273,756
Indirect Cost
$9,487
Name
Sarc
Department
Type
DUNS #
186146911
City
Ann Arbor
State
MI
Country
United States
Zip Code
48106
Schaefer, Inga-Marie; Mariño-Enríquez, Adrián; Fletcher, Jonathan A (2017) What is New in Gastrointestinal Stromal Tumor? Adv Anat Pathol 24:259-267
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Chen, James L; David, Jason; Cook-Spaeth, Douglas et al. (2017) Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease. Mol Cancer Res 15:26-34
Alomari, Ahmed K; Brown, Noah; Andea, Aleodor A et al. (2017) Cutaneous syncytial myoepithelioma: A recently described neoplasm which may mimic nevoid melanoma and epithelioid sarcoma. J Cutan Pathol 44:892-897
Hayashi, Masanori; Baker, Alissa; Goldstein, Seth D et al. (2017) Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma. Oncotarget 8:78265-78276
Svoboda, Laurie K; Bailey, Natashay; Van Noord, Raelene A et al. (2017) Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin. Oncotarget 8:458-471
Schaefer, Inga-Marie; Wang, Yuexiang; Liang, Cher-Wei et al. (2017) MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nat Commun 8:14674
Davis, Lara E; Janeway, Katherine A; Weiss, Aaron R et al. (2017) Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer 123:3434-3440
Haak, Andrew J; Appleton, Kathryn M; Lisabeth, Erika M et al. (2017) Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma. Mol Cancer Ther 16:193-204
Lee, Jen-Chieh; Li, Chien-Feng; Huang, Hsuan-Ying et al. (2017) ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol 241:316-323

Showing the most recent 10 out of 104 publications